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Abstract: This paper presents a comprehensive review of research relating psychological domains with response to therapy in patients 
with rheumatoid arthritis. A holistic approach to the disease was adopted by incorporating not only disease activity but also dimensions 
of the impact of disease on patients’ lives. Psychological distress, including depression and anxiety, is common among patients with 
rheumatoid arthritis and has a significant negative impact on response to therapy and on patients' abilities to cope with chronic illness. 
Evidence regarding the influence of positive psychological dimensions such as acceptance, optimism, and adaptive coping strategies is 
scarce. The mechanisms involved in these interactions are incompletely understood, although changes in neuro-endocrine-immune path-
ways, which are common to depression and rheumatoid arthritis, seem to play a central role. Indirect psychological influences on thera-
peutic efficacy and long-term effectiveness include a myriad of factors such as adherence, placebo effects, cognition, coping strategies, 
and family and social support. Data suggest that recognition and appropriate management of psychological distress may improve re-
sponse to treatment and significantly reduce disease burden. 
Keywords: Psychological factors, depression, coping, treatment, rheumatoid arthritis, placebo, psychological adjustment, psychoneuroimmu-
nology.  
INTRODUCTION  
 The prevalence of clinical depression and anxiety in patients 
with rheumatoid arthritis (RA) is almost double that of the general 
population. After adjustment for gender, age, marital status, in-
come, and health conditions other than RA, the estimated odds ratio 
of depression is 1.63 (95% CI, 1.43- 1.87) for patients with RA, 
compared to the general population [1]. When clinical depression 
and self-reported measures of depressive mood are included in es-
timates, prevalence has been shown to be 13-42% in patients with 
RA, and the condition is often unrecognized and undertreated [2, 3, 
4]. Anxiety is also 2 to 4 times more prevalent in RA than in the 
general population and often overlaps with depression [5]. The 
impact of psychological distress on response to treatment in RA is 
increasingly recognized [2, 6, 7], thus generating renewed interest 
in the psychological factors associated with response to treatment. 
The mechanisms underlying these factors remain largely unclear. 
However, given that similar biological systems and mediators are 
involved in psychological distress and inflammation, ample and 
complex opportunities for bidirectional interaction arise [8, 9]. Psy-
chological distress can affect disease activity and response to treat-
ment by altering the functioning of the immune, endocrine, and 
central nervous systems. 
 Health behavior is another vast field encompassing potential 
psychological influence on response to treatment and comprises 
factors such as adherence, smoking, exercise, obesity, visits to the 
doctor, and cognition, all of which affect pain and other parameters 
of disease activity and impact. Knowing and understanding the 
influence of psychological factors underlying response to treatment 
and the mechanisms involved could provide important information 
for selection of therapy, evaluation of response, and even targeted 
psychological interventions aimed at optimizing patient outcome. In 
this paper, we review the evidence for an association between psy-
chological factors and response to treatment in RA. The review 
addresses 3 issues: 1) evidence for psychological factors that affect  
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the response to treatment in RA, 2) potential mechanisms underly-
ing these factors, and 3) interventions used to benefit the patient.  
1. EVIDENCE FOR PSYCHOLOGICAL FACTORS AF-
FECTING RESPONSE TO TREATMENT IN RA  
1.A. Depression, Anxiety, and Efficacy of Therapy  
 The best evidence for the effect of emotions on response to 
treatment is provided by randomized control trials, in which poten-
tial confounders, such as adherence and expectations, are randomly 
distributed. The COMET [COmbination of Methotrexate (MTX) 
and ETanercept (ETN)] trial compared the effects of methotrexate 
with and without etanercept in 542 patients with RA. A report on 
this study published in 2011 analyzed 389 patients with data from 
the Hospital Anxiety and Depression Scale at baseline and subse-
quent visits during the 2 years of follow-up [10]. Among patients 
who had symptoms of depression or anxiety at baseline, signifi-
cantly fewer had clinical remission, low disease activity, and nor-
mal functioning at the 2-year follow-up, even after correction for 
baseline disease activity levels. The bidirectional nature of these 
factors is highlighted by the observation that patients who achieved 
clinical remission less frequently had persistent symptoms of de-
pression or anxiety compared with non-remitters. The relationship 
between baseline depression and objective outcome measures was 
not only driven by tender joint count or patient global health re-
ports, which might be considered more prone to psychological in-
fluence, but also by correlations between depression and (more) 
objective measures (ie, erythrocyte sedimentation rate [ESR] and 
swollen joint count), which were also statistically significant. At 
baseline, patients with depression had significantly worse measures 
of inflammation and disease activity (C-reactive protein [CRP], 
ESR, and DAS28 [disease activity score including the assessment 
of 28 joints]) compared with those without depression. In contrast 
to depression, anxiety showed no relationship with ESR or CRP. 
These controlled observations are well aligned with the results of 
observational studies indicating that depression at baseline and, 
more particularly, persistent depression during treatment are associ-
ated with higher levels of disease activity at all times and negatively 
affect the rates of remission and low disease activity achieved using 
anti-tumor necrosis factor (TNF) therapy [11, 12]. Therefore, rec-
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ognition and appropriate management of depression could improve 
the effectiveness of anti-TNF therapy. These psychological influ-
ences on response to treatment are especially relevant when adopt-
ing a holistic approach to the assessment of response to therapy by 
incorporating relevant patient-reported outcomes (PROs), such as 
quality of life and fatigue, alongside depression and anxiety [10]. 
We could not find any studies addressing the potential influence of 
psychological domains on response to medication in controlled 
circumstances.  
1.B. Disease Activity in the Clinical Setting and Associated Psy-
chological Factors: Stress and Personality 
 Although many patients with RA attribute their disease flares to 
psychological stress, research results are not conclusive [13]. Data 
indicate that enduring minor and interpersonal stressors can be re-
lated to concurrent or subsequent increases in disease activity [14-
16]. The study by Zautra is especially interesting, the disease activ-
ity increases in association with stress, and concurrent depression 
was mirrored by higher levels of circulating interleukin (IL) 6. An-
other study revealed a significant relationship between minor stress-
ful events and disease activity [14]. Such interactions have been 
questioned by studies with negative results [13, 15, 17]. To date, 
studies on the relationship between personality traits, disease activ-
ity, and response to treatment are scarce and inconclusive [18]. 
 A prospective study of patients with RA showed neuroticism to 
be a strong determinant of persistent low mood [19]. In their cross-
sectional study, Persson et al. (2002) found data to suggest that 
neuroticism is strongly associated with self-rated symptoms and 
well-being in RA [20]. Conversely, disease activity can influence 
the expression of personality traits: Hyphantis et al. (2006) found 
that during exacerbations of disease activity in early RA patients, 
personality profiling revealed characteristics of a borderline person-
ality disorder [21]. The design of the study did not allow conclu-
sions to be drawn regarding the nature and direction of causal rela-
tionships. Coping strategies are decisive modulators of the impact 
of disease on a patient’s function and quality of life. 
 A recent review addressing the longitudinal association be-
tween coping and psychological distress in RA found evidence that 
maladaptive cognitive coping styles and patterns such as pessi-
mism, catastrophizing, and cognitive distortions are associated with 
increased levels of psychological distress [22]. In osteoarthritis, 
catastrophizing is a determinant of pain, psychological disability, 
and physical disability [23], and increases in psychological distress 
have been observed to predict increases in osteoarthritis pain [24]. 
Somatization, the interpretation of innocuous bodily sensations as 
symptoms of disease, has been shown to exert a strong influence on 
health-related quality of life in RA, even after controlling for pain. 
In fact, the number of physical symptoms is affected by concurrent 
anxiety and depression, neuroticism, and negative affect at least as 
much as by objective measures of disease activity and cumulative 
joint damage [21]. Psychological aspects are obviously pivotal 
when considering lifestyle factors associated with disease activity 
and response to treatment in RA. 
 There is strong evidence to support the concept that a compre-
hensive treatment strategy for RA should include correction of ex-
cessive body weight and cessation of smoking. Both of these condi-
tions are associated with severity of RA and reduce the efficacy of 
anti- TNF agents [25, 26]. However, moderate alcohol consumption 
may decrease the severity and progression of RA, possibly by re-
ducing levels of some inflammatory mediators [27- 29]. Excessive 
drinking will certainly increase the risk of liver toxicity for a variety 
of drugs, including MTX. Aerobic and strengthening exercises have 
been shown to provide significant improvements in the physical and 
psychological status of RA patients, including reduction in pain and 
fatigue and increased sense of well-being [30-32]. Obesity, smok-
ing, and lack of exercise have all been related to higher levels of 
stress. However, it is not clear whether stress plays a role in mediat-
ing their effect on disease activity and response to treatment. In any 
case, health behaviors and their modulation have a considerable 
impact on disease management. During the last decade, self-
efficacy has arisen as one of the most important psychosocial vari-
ables when considering pain and disability in people with RA [33, 
34]. Self-efficacy is the belief that one is capable of performing 
competently in specific situations. 
 RA patients who report higher levels of self-efficacy experience 
less pain, physical disability, fatigue, and negative mood [35, 36]. 
 A study of 75 women with RA using questionnaires and a sem-
istructured interview found that the group of patients who could 
better control the symptoms of RA described significantly lower 
levels of depression, pain, and physical disability [37]. 
 Increases in self-efficacy that arise over the course of training in 
self-management or pain coping skills significantly predicted en-
hancements in RA pain, health status, and depression [38].  
1.C. Psychological Factors Influencing the Effectiveness of 
Therapy  
 Long-term persistence and effectiveness of treatment in clinical 
practice is affected by factors that are often ignored in short-term 
clinical trials, namely, adherence, co-medication, and late adverse 
events. Observational studies are best suited to address these as-
pects and take into account a diversity of relevant outcomes not 
considered in short-term trials. Depression has been consistently 
associated with worse disease outcomes in patients with RA, in-
cluding pain, tender joints, poor adherence to medication, increased 
healthcare service utilization, disability, and higher rates of early 
retirement [2, 5, 39-42]. Conversely, several studies have demon-
strated that functional disability and loss of valued activities, such 
as employment, are associated with an increased risk of depression 
[39, 42, 43]. In addition, depression has been identified as an inde-
pendent risk factor for cardiovascular disease, myocardial infarc-
tion, suicide, and all-cause mortality in patients with RA [44, 45]. 
The literature contains few references to the influence of psycho-
logical factors on the results of surgical management. A recent sys-
tematic review of factors involved in the perioperative management 
of major lower limb arthroplasty found that RA patients with clini-
cal depression do not improve to the same extent as those without 
[46].  
2. POTENTIAL MECHANISMS INVOLVED IN FACTORS 
AFFECTING RESPONSE TO TREATMENT  
2.A. Interactions between Psychological Domains and Biological 
Mechanisms of RA  
 It has been repeatedly demonstrated that then immune system 
plays a pivotal role in the biology of a large array of psychiatric 
disorders, including not only major depression but also schizophre-
nia and autism [47-49]. Such observations support the possibility 
that the immune system plays a key pathophysiological role in the 
concomitant development and progression of psychopathology and 
autoimmune disorders. Depression and depressed mood are associ-
ated with a proinflammatory cytokine spectrum, as measured in 
peripheral blood. A recent meta-analysis confirmed that patients 
with depression have significantly higher levels of circulating TNF-
alpha and IL-6 than nondepressed age-matched controls. No sig-
nificant differences were found for IL- 1, IL-2, IL-4, IL-8, IL-10, 
or interferon [IFN]  [50]. CRP also seems to be increased in de-
pression [51, 52]. Moreover, it has been demonstrated that persis-
tence of immune activation after treatment of major depression is a 
risk factor for relapse during the following months [53, 54]. There 
is abundant circumstantial evidence to support these findings. De-
pression has been shown to occur with remarkable frequency after 
immune challenges such as vaccination [55], administration of en-
dotoxin [56], and anti–IFN- therapy [57]. Conversely, there is 
evidence that anti-inflammatory therapies can relieve depressive 
symptoms in the absence of somatic disease [48, 58, 59]. Antide-
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pressive drugs have immunomodulatory effects. Despite conflicting 
results, their effect seems to be predominantly immunosuppressive, 
namely, a shift from TH2 to TH1 cytokine response patterns and 
decrease in levels of TNF-alpha, IL-1, and IL-6 while maintaining 
or increasing levels of anti-inflammatory cytokines such as IL-4 
and IL-10 [60, 61]. Sertraline, a selective serotonin reuptake inhibi-
tor (SSRI), was recently shown to decrease adjuvant-induced arthri-
tis in rats as potently as MTX. This effect was associated with a 
significant increase in levels of the anti-inflammatory cytokine IL-
10, a decrease in TNF-alpha levels, and a decrease in cyclooxy-
genase-2 production [62]. Similarly, the SSRI fluoxetine has been 
shown to promote remission in an experimental model of autoim-
mune encephalomyelitis [63]. Individual case reports suggesting 
similarly remarkable effects of antidepressants in RA do not pro-
vide proof, but may boost our interest in researching this field [64].  
 In summary, depression is associated with a proinflammatory 
cytokine environment in the absence of any overt inflammatory 
condition and can be induced by immune challenges. Immuno-
modulators can influence the risk and expression of various psycho-
logical conditions and states. Immune mediators and autoimmune 
conditions can be modulated by psychoactive drugs. Such observa-
tions offer a myriad of possible bidirectional interactions between 
mood disorder and RA. Increased activity of RA when associated 
with depression and stress may be conceived as a simple reflection 
of the coexistence of 2 inflammatory conditions. The increased 
resistance to therapy in these circumstances may be related to the 
additional load of inflammatory mediators. Conversely, the in-
creased prevalence of depression in RA and its amelioration with 
anti-TNF therapy may simply reflect the ability of the proinflamma-
tory cytokines IL-6 and TNF-alpha to induce depression and sick-
ness [51, 65]. Relief from depression when RA is in remission may 
be a direct effect of therapy on the biology of depression, at least as 
much as an indirect effect through improvement in the symptoms of 
RA and its impact on the patient’s ability to enjoy life. In psoriasis, 
a randomized controlled trial of etanercept found that patients re-
ceiving anti-TNF-alpha drugs gained significant relief from depres-
sive symptoms independently of improvement in disease activity, 
thus indicating a possible direct influence of TNF-alpha on depres-
sion [66]. It has been proposed that blockade of proinflammatory 
cytokines with biologics could represent a new approach to treating 
depression [67] that could also prove to be useful in inflammatory 
conditions such as RA. The neuroendocrine biology of RA provides 
several potential avenues for bidirectional psychological interac-
tions. Similarly to immune challenge, acute psychological stress is 
associated with overactivation of the hypothalamic-pituitary-
adrenal (HPA) axis, resulting in increased levels of circulating cor-
tisol and activation of the autonomic nervous system. Cortisol sup-
presses inflammation through an array of mechanisms, including 
inhibition of the production of proinflammatory cytokines. These 
findings suggest that stressful circumstances would decrease in-
flammatory responses and ameliorate inflammatory conditions [68, 
69]. However, chronic stress has a different biology: under persis-
tent activation, the HPA axis eventually reduces the production of 
glucocorticoids, and persistent stress results in significant down-
regulation of the expression of glucocorticoid receptors. The same 
finding is observed in chronic persistent systemic inflammation. 
Chronic stress actually results in diminished levels of circulating 
glucocorticoids relative to levels that would have been adequate 
given the intensity of concomitant inflammation or psychological 
distress. These relatively low levels of circulating glucocorticoids 
act upon desensitized target cells [70, 71] and thus favor the in-
crease in proinflammatory cytokine level and foster chronic in-
flammation. This paradoxical inhibition of glucocorticoid produc-
tion in chronic stress and/or inflammation occurs mainly at the level 
of the adrenal response to adrenocorticotropic hormone. The pro-
duction of corticotropin-release hormone (CRH), induced by both 
psychological stress and proinflammatory cytokines (IL-6, TNF), 
remains elevated in chronic distress. Increased CRH levels contrib-
ute directly to depression through special type II CRH receptors in 
the central nervous system [71, 72]. Antidepressants also influence 
these mechanisms, for example, by increasing glucocorticoid recep-
tor expression and function [73, 74]. Studies on depressed patients 
found that the long-term effectiveness of antidepressant therapy 
depends on the correction of HPA axis hyperactivity [75, 76]. De-
pression is also associated with low levels of melatonin in plasma 
and urine and alteration of circadian rhythms in RA patients. Mela-
tonin and sleep have complex interactions with the immune system. 
 Humoral and cellular immunity are significantly influenced by 
melatonin through specific receptors, selective melatonin receptor 
MT1/MT2, and high-affinity nuclear receptors, which are found on 
leukocytes. 
 Melatonin inhibits translocation of NF-B to the nucleus, thus 
reducing the production of proinflammatory cytokines such as IL-6 
and TNF-alpha. However in most circumstances, this hormone 
seems to have a predominantly anti-adrenocortical and anti-stress 
action. 
 Antidepressives have shown to raise melatonin levels in de-
pressed patients and to promote the restoration of biological 
rhythms [61]. While these interactions are incompletely understood 
at present, they do have potential in this field. The evidence briefly 
summarized above demonstrates that there is an overlap between 
the biological mechanisms underlying conditions classically con-
sidered diverse and independent, namely, autoimmune and other 
inflammatory diseases on the one hand and psychological condi-
tions and traits on the other. This overlap provides potentially am-
ple biological bidirectional communications and effects between 
these mechanisms.  
2.B. Psychological Dimensions Associated with Patient-
Reported Outcomes and the Impact of Disease on Patients’ 
Lives  
 PROs are becoming increasingly relevant as measures of dis-
ease activity and response to therapy [77]. Given that these meas-
ures are more prone to emotional influence than the DAS28, the 
scientific community questions their validity and reproducibility. 
However, such criticism must be reconsidered if we recognize that 
they convey dimensions of disease and illness that are indispensible 
if we are to grasp the full impact on patients, in other words, the 
true importance of disease. Arthritis has intrinsically subjective 
dimensions, including pain, fatigue, depression, and anxiety, and 
these dimensions are as representative of disease burden as the 
number of swollen joints. 
 The RA Impact of Disease (RAID) score conveys patients’ 
views on the impact of RA [78]. The more than 500 patients who 
were involved in the development of the RAID score identified 7 
major domains as representing the overall burden of the disease: 
pain (21%), functional disability (16%), fatigue (15%), emotional 
well-being (12%), sleep disturbance (12%), coping (12%), and 
physical well-being (12%) [79]. This study shows that patients 
consider emotions an integral part of their disease. Therefore, de-
pression, anxiety, and other psychological dimensions such as help-
lessness, fear, and invalidation should not be seen as extrinsic fac-
tors undermining the reliability of the “true measures of disease 
activity”, but as valid “additional measures of disease”. We will fail 
to grasp the disease completely if we insist on keeping emotions 
and other subjective dimensions out of the equation. Below, we 
discuss each of the domains elected by patients to describe the im-
pact of RA (RAID score) and explore their psychological dimen-
sions.  
Pain  
 A cross-sectional study showed strong associations between the 
severity of pain, sleep disturbances, and depression [80]. Given the 
biological pathways revised above, it is conceivable that these in-
fluences might be mediated by increased inflammation. However, 
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Kojima et al. (2009) observed that severity of depression is posi-
tively associated with pain in patients with RA independently of the 
intensity of inflammation as measured by other parameters [81]. 
Depression, anxiety, and chronic stress have been shown to de-
crease the pain threshold and increase sensitivity to pain of different 
origins in humans and experimental pain in animals: pressure pain, 
thermal pain, visceral pain, formalin-induced hyperalgesia, and 
responsiveness to repetitive noxious mechanical stimuli (wind-up) 
[82-84]. It is difficult to ascertain the effect of emotions on disease 
activity and pain threshold in human disease, as one emotion tends 
to affect another. However, it seems reasonable to conceive that 
both the disease process and pain are affected by emotions.  
Functional Disability  
 Studies indicated that the Health Assessment Questionnaire 
score, the most frequently used measure of physical disability in 
RA, is associated with depression [85] and pain [2]. It has also been 
suggested that loss of valued activities caused by long-term disabil-
ity and joint damage leads to depression [86]. Fatigue and pain also 
increase physical disability [87].  
Fatigue  
 Although fatigue is a likely consequence of the disease process 
in RA [89], previous reports have shown that it is associated with 
pain and depression [90, 91], more strongly so than with other pa-
rameters of disease activity [87]. Psychosocial factors including 
health beliefs, perception of illness, and poor social support may 
influence the fatigue associated with RA [36, 92].  
Emotional Well-being  
 Patients consider emotions an important outcome of their dis-
ease [79]. Studies have shown that quality of life is significantly 
lower in patients with RA than in patients with other inflammatory 
conditions, because their depression or anxiety scores are higher 
[93, 94].  
 Kojima et al. (2009) suggested that disease activity evaluated 
by routine objective clinical examinations does not mirror the 
physical and mental quality of life of RA patients [81]. Clinicians 
should assess the psychosocial status, as well as their subjective 
disease status, in order to improve quality of life of RA patients 
[85]. This observation is coherent with the findings of Persson et al, 
who suggested that psychological factors performed better than 
disease activity as predictors of well-being among RA patients [95]. 
Interestingly, a subanalysis of the COMET study involving active 
early RA patients demonstrated that clinical remission with drug 
treatment is associated with improvement of PROs such as depres-
sion and anxiety [10]. In summary, it seems reasonable to expect 
that the abrogation of the inflammatory process in RA will assist in 
controlling depression and anxiety in some but not all patients. 
Thus, comorbid depression and anxiety must be evaluated and 
taken into account when trying to assess and control the impact of 
RA on patients’ lives [94].  
Sleep Disturbances  
 Sleep disturbances have been associated with higher levels of 
pain, fatigue, and depression in patients with RA [96-98]. In a lon-
gitudinal analysis, Nicassio et al. (1992) found that pain can exac-
erbate sleep disturbances in RA patients, and that both factors can 
contribute to depression over time [99]. Additionally, sleep depriva-
tion can cause musculoskeletal pain, even in healthy people, and it 
adds to fatigue and to decreased overall sense of well-being. 
Moreover, sleep deprivation has been shown to result in higher 
circulating levels of CRP, prostaglandin E2, and IL-6 [100].  
Coping Styles and Strategies 
 The stress-coping model has been widely used to understand 
psychological adjustment to RA. Coping refers to the cognitive and 
behavioral efforts that people make to manage situations that are 
considered as stressful [101]. Numerous coping strategies have 
been differentiated (eg, problem- focused vs emotion-focused, ac-
tive vs passive, and engagement vs disengagement) and categorized 
employing a hierarchical taxonomy of coping [102]. RA patients 
adopting passive coping strategies (especially avoidance, helpless-
ness, and wishful thinking) tend to have more pain and higher de-
grees of disability [22, 103, 104]. 
 Cross-sectional studies consistently showed that avoidance -
oriented coping is linked to poor psychological well-being [105, 
106]. Catastrophizing has been found to be especially harmful for 
daily functioning in patients with RA [107] and in patients with 
other rheumatic conditions such as low back pain, fibromyalgia, 
and osteoarthritis [108]. In this regard, people with RA may be 
hypersensitive to certain stressors and/or generate a more marked 
response to stress [109]. While the use of active coping strategies is 
usually found to be helpful, in instances where it is not possible to 
change the stressor, continued attempts at problem solving may 
result in heightened distress. It has been suggested that coping 
flexibility, ie, the use of a variety of coping strategies in different 
situations, may be the most beneficial factor for adjustment to RA, 
particularly because of the fluctuating and often unpredictable 
course of the disease [110]. The concepts of “locus of control” and 
“self-efficacy” also deserve consideration in this context. Patients 
with an internal locus of control are more likely to take control of 
their health, feel capable of developing strategies to deal with pain 
(self-efficacy), and report lower pain intensity [111]. On the other 
hand, those with an external locus of control have low confidence 
in their ability to manage and reduce their pain and may thus avoid 
intensifying their activity level [112]. 
 In a cross-sectional study of 70 RA patients, it was suggested 
that patients with both a high internal locus of control and high self-
efficacy described better health status than patients with a low in-
ternal locus of control and low self- efficacy [113]. Moreover, 
higher levels of self-efficacy for physical activity increase the prob-
ability that patients with RA will achieve their physical activity 
goals [114]. Finally, increasing self-efficacy beliefs is a common 
ingredient of cognitive-behavioral therapy and has proven effective 
[38]. Spiritual and religious resources are relatively recent areas of 
study in pain research. Both can have a substantial impact on the 
patient’s perception of pain, suffering, and disease burden. A multi-
center cross-sectional study of 580 patients [115] showed signifi-
cant associations between spiritual resources, positive appraisal, 
and internal adaptive coping strategies, suggesting that spiritual 
resources go beyond fatalistic acceptance and actually operate as an 
active coping strategy.  
 In a meta-synthesis analyzing the status of spiritual well-being, 
the investigators identified four consistent situations related to RA 
patients' spiritual well-being: living with the disease, reclaiming 
control, reframing the situation, and bolstering courage [116]. The 
authors highlight that spiritual well-being should be incorporated 
into quality of life evaluations of RA patients and may afford an 
evaluation tool able to explain the variability of the effectiveness of 
various interventions. In a recent case-control study [117], the 
authors found that 637 patients with RA and 496 healthy controls 
score differently on 8 specific domains of the Trait Emotional Intel-
ligence Questionnaire. The RA group scored higher on relationships 
and empathy and lower on stress management, emotion manage-
ment, adaptability, assertiveness, impulsiveness, and self-esteem 
(p<0.0025). 
 In summary, coping strategies play a key role in determining 
the impact of similar disease conditions on suffering, pain, disabil-
ity, and enjoyment of life. Physicians frequently recognize this in 
their practice, although a structured approach to the assessment and 
training of coping strategies is usually absent.  
2.C. Psychological Influences on Measures of Disease Activity 
and Response to Therapy  
 Placebo and nocebo effects - Psychological influences on pain, 
suffering and modulation by medical treatment.  
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 In randomized clinical trials of DMARDs, 15-35% of patients 
with RA respond to placebo according to the American College of 
Rheumatology (ACR) 20% criteria. Improvements are usually evi-
dent within 1-3 months and may persist for as long as 12 months 
[118, 119]. A meta-analysis of placebo response in osteoarthritis 
[120] confirmed an appreciable effect size of placebo in the treat-
ment of this condition, particularly for subjective outcomes (pain, 
stiffness, self-reported function) and the doctor’s global assessment. 
Placebo seems to have no effect on more objective outcomes, such 
as range of motion. The contextual features underlying the placebo 
effect have been closely studied in pain and may reflect nonspecific 
aspects of the patient-physician relationship, including attention, 
compassionate care, modulation of expectations, anxiety, and self-
awareness [121]. Curiously, in a multicenter randomized controlled 
trial of a new agent for RA resistant to MTX, ACR20 response rates 
in both the placebo and active drug groups were higher among pa-
tients from Latin America and Eastern Europe than patients from 
the USA [122]. Some authors have hypothesized that patients with 
RA from economically disadvantaged countries with a lower socio-
economic status and lower educational level have a substantially 
poorer clinical status than those from developed countries, who 
have considerably greater capacity for improvement [123]. It could 
also be argued that the opportunity of receiving such new agents 
can be expected to have a much higher emotional bearing—and 
thus potential placebo effect—in developing countries. The deter-
minants of the magnitude of the placebo effect on osteoarthritis 
pain were identified in a meta-analysis of randomized controlled 
trials: the pain-relieving effect of placebo was greater when the 
active treatment effect, the baseline level of pain, and the sample 
size were higher and when placebo was administered by injection 
[120]. Interestingly, the placebo effect increases as the effect size of 
treatment increases. This finding suggests that a higher level of 
expectation of benefit by participants (and assessors), as reflected in 
the placebo effect, is also part of the effect of the experimental 
medication [120, 124]. In any case, the data from this meta-analysis 
suggest that placebo is truly more effective as an analgesic over 
nontreatment (observation only). The superior placebo effect in this 
meta-analysis was observed in studies with larger samples, suggest-
ing that in the presence of superior placebo effects, larger samples 
are needed to show significant differences and positive studies have 
a higher chance of publication than negative ones (publication bias) 
[120]. In fact, numerous neurofunctional studies have now estab-
lished beyond reasonable doubt that the effect of placebo on neu-
ronal activity at CNS sites associated with modulation of physical 
pain is similar to that of analgesics [125, 126]. This means that 
placebo significantly changes the pain experience and, therefore, 
the perception of painful disease. A similar yet contrary effect is 
observed with nocebo, ie, the detrimental effect induced by nega-
tive cognitions [127]. Although the scientific method has endeav-
ored to separate placebo effect from active medication effects, we 
must recognize that, when it comes to pain, placebo effects are at 
least as real as those achieved with active medication. The efficacy 
of “proven effective” medication also incorporates the placebo 
effect and would certainly be diminished by efforts to exclude any 
influence of context on the effect of medication by diminishing the 
placebo effect. Systematic reviews show that the doctor-patient 
relationship has an important therapeutic effect, irrespective of 
prescribed treatment. 
 Physicians who assume a warm, friendly, and calming style are 
more effective than those who maintain consultations formal and do 
not offer encouragement [128].  
The DAS Score and its Components  
 Results from the COMET study show that the self-assessed, 
subjective parameters of disease activity (ie, tender joint count and 
global health reports) had a stronger association with depression 
than the objective parameters (swollen joint count and ESR), al-
though the correlation was statistically significant in both cases 
[10]. However, one should refrain from assuming that depressed 
patients exaggerate in their assessment of tender joints or global 
health. As outlined above, there is abundant reason to assume that 
depression may actually change the disease and its impact on the 
patient. Cross-sectional studies provide conflicting results, with 
most describing an association between depressed mood and objec-
tive measures of disease activity, such as CRP and ESR [6, 11, 81, 
129, 130]; however, others do not find such associations [131, 132]. 
Some authors have found that anxiety does not correlate with ESR 
or CRP in RA patients [10, 133], whereas others show that anxiety 
and disease activity were positively associated when measured 
simultaneously and 6 months apart [6]. While the latter study found 
some support for the condition that a higher level of disease activity 
is a risk factor for increased psychological distress, the findings did 
not confirm the hypothesis that psychological distress is a risk fac-
tor for future exacerbation of disease activity. 
 Furthermore, in patients with RA and concomitant/secondary 
fibromyalgia, DAS28 has been reported to overestimate disease 
activity [124, 125], possibly because of application of the visual 
analog scale for general health and tender joint count, which focus 
on the more subjective components of DAS28 [48]. These authors 
suggested that in order to reliably estimate an individual’s disease 
activity, the individual components of DAS28 should also be exam-
ined, and that if the 2 measures listed above are high relative to 
ESR and swollen joint count, tender joints should be assessed. In 
the study by Mattey et al. (2010), discontinuation of anti-TNF was 
associated with depression, anxiety, and disease activity at baseline, 
suggesting that disease activity and psychological distress also in-
dependently predict the effect of biologics [12].  
2.D. Influence of Psychological Factors on Long-Term Effec-
tiveness of Treatment  
 Many factors can negatively influence the long-term effective-
ness of drugs that have been shown to be efficacious in shorter 
clinical trials. Most of these relate to cognitions and behavior, thus 
entering the realm of psychological domains.  
Adherence, Beliefs, Expectations, and Communication  
 Reported adherence rates in RA vary from 30% to 93% [34, 
134]. This will forcibly have a high impact on the results of treat-
ment in clinical practice. Expectations regarding the effects and 
side effects of therapy are essential for successful adherence [135]. 
Female gender, middle age, busy lifestyle, cognitive deficits, de-
pression, higher income, and employment status have all been asso-
ciated with nonadherence [136, 137]. Garcia- Gonzalez et al. 
(2008) found that Hispanic and African American patients have 
significantly lower levels of adherence to medication than Cauca-
sian patients [138]. The authors attributed these findings to a 
stronger feeling of depression and perceptions of medication as 
harmful in ethnic minorities. Similar findings have been reported by 
Kumar et al. (2008), who compared South Asian patients with Cau-
casian British patients [139]. Health expectations and patient atti-
tude also influence the kinds of treatments that can be realistically 
offered. Psychological aspects of the prescribing physician and 
divergence between patients and physicians also play a role. For 
example, patients with early RA were less reluctant to accept com-
bination therapy with conventional DMARDs and biologics than 
rheumatologists [133-136], and a study analyzing the European 
League Against Rheumatism Recommendations on the manage-
ment of glucocorticoid therapy demonstrated important discrepan-
cies between patients’ and rheumatologists’ perspectives that might 
negatively affect the implementation of the recommendations [137]. 
Such beliefs and divergence need to be addressed, as they may 
unduly interfere with the physician’s selection of therapy and with 
the patient’s commitment to the strategy. Communicating, discuss-
ing the goals and alternatives of the treatment with the patients, and 
making joint decisions seem to be essential for achieving optimal 
adherence [48, 140].  
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Social Aspects of Response to Therapy  
 Psychological aspects can both influence and be influenced by 
social context. Examples include the presence or absence of en-
couragement by family, social support, and invalidation, as well as 
aspects related to cultural/geographical background and gender. RA 
is especially challenging for spouses or partners. 
 Both partners and patients may lack the confidence to commu-
nicate effectively about fatigue and pain and resist discussing pain-
related topics with each other.  
 Partners who resist discussing pain (eg, overprotective partners) 
reveal higher levels of caregiver tension, and their patient partners 
described much higher levels of psychological disability and pain 
catastrophizing [141]. Furthermore, depressed partners may experi-
ence coping problems with a chronic illness. High levels of spousal 
depressive symptoms, for example, have been shown to predict 
worsening of disability and disease activity over a 1-year period 
[23, 142]. Well-intentioned people close to the patient can offer 
unhealthy social support. Spouses who, for instance, in an assertive 
and lecturing way “know” what is best for the patient can impede 
the patient’s feeling of independence and self-control [143]. 
 Lack of reciprocity in a relationship, ie, obtaining more support 
than one provides (over- benefit) and providing more support than 
one receives (under-benefit) is psychologically distressing [144]. 
Social support beyond the immediate family is critical in the ad-
justment to RA. 
 Obtaining support from others generally results in mental bene-
fit and physical health and may dampen the destructive impact of 
disease stressors or external stressors, as shown in patients with 
fibromyalgia [145] and in patients with RA [146]. Patients with RA 
may benefit from emotional social, informational, behavioral, or 
tangible forms of social support. 
 High levels of social support, such as (the perception of) being 
cared for and having assistance available from family and friends, 
may protect against anxiety [133]. Workplace support can help 
individuals to adjust better to painful disorders. Li (2006) found that 
patients who reported low workplace support were much more 
likely to develop depressive symptoms within 18 months [42]. Few 
studies have investigated the interaction between cul-
tural/geographical background and response to treatment in RA. 
Recent studies found racial/ethnic differences in PROs of function 
and global disease assessments [147, 148]. These discrepancies 
could result from differences in interpretation and completion of 
outcome instruments, which, although often transculturally vali-
dated, may not guarantee transcultural comparability of results.  
3. INTERVENTIONS USED TO BENEFIT THE PATIENT 
Treating Depression/Anxiety  
 Given its impact on the patient’s quality of life, clinically overt 
depression associated with RA should be treated as a separate en-
tity, as long as there are no contraindications. The evidence that 
concomitant depression hinders the efficacy of DMARDs further 
supports the need to systematically look for and treat depression in 
RA. This assertion holds, even if effective treatment with biological 
agents such as infliximab, etanercept, or adalimumab has been 
shown to reduce the prevalence of depression in RA patients. Yet, it 
remains unclear whether antidepressants and psychological thera-
pies confer their expected benefits in patients with RA who are 
diagnosed with an anxiety disorder or depression according to es-
tablished criteria [4]. The possibility of using antidepressants or 
psychological interventions for depression with the intention of 
improving RA (especially, but not only, in the presence of con-
comitant depression) is appealing and biologically plausible. Unfor-
tunately, this possibility has never been formally tested. Antide-
pressants have a beneficial effect on pain and reduce disease activ-
ity in patients with RA [149]. However, the impact of antidepres-
sants or cognitive behavioral therapy on broad healthcare outcomes 
such as disease activity, disability, and health status has not been 
established for persons with RA [150]. At present we can only 
speculate that, since treatment with antidepressants is associated 
with reduced levels of proinflammatory cytokines, these drugs hold 
promise as adjuvant therapies for RA, especially in patients with 
depression. 
 Psychological interventions have also been expanded for pa-
tients with rheumatic diseases and relatively high scores for anxiety 
or depressive symptoms but who do not fulfill the established diag-
nostic criteria for these conditions. Evidence showed that over and 
above standard care, psychological interventions can successfully 
improve physical and psychological performance and reduce long-
term consumption of medical resources [151-154]. 
 A meta-analysis of randomized controlled trials in RA demon-
strated that cognitive- behavioral therapies are effective at improv-
ing pain, disability, coping, self-efficacy, and psychological dis-
tress, with small to moderate effect sizes [151].  
Can we Use the Placebo Effect to Benefit the Patient? 
 One review highlighted the placebo effect and some determi-
nants of “placebo responses” [155]. Treatments that are perceived 
as being more powerful tend to have a stronger placebo effect than 
those that are perceived to be less so. 
 Furthermore, the same substance has been found to be more 
powerful when it is branded than when it is not. Greater placebo 
effects have been reported with injections than with oral medication 
in many conditions. Moreover, adherence to what the patient be-
lieves to be a beneficial treatment is itself beneficial to health out-
comes [156, 157]. The environment in which the patient receives 
treatment may also modify outcome. Patient-physician communica-
tion plays a key role in the placebo response. A positive consulta-
tion is one where the physician gives a confident diagnosis, is opti-
mistic that the treatment will help and be safe, wants to monitor the 
patient’s progress, and reassures the patient that things will improve 
soon. Addressing the patients’ concerns and misinterpretations may 
reduce the nocebo effects of fear and diminish the risk of intoler-
ance and early treatment withdrawal.  
 Although there is no general opinion on the role of placebo and 
how to optimize it, practicing clinicians know that they would pay a 
disservice to their patients if they disregarded it and, even more, if 
they tried to avoid it. Physicians recognize hope as an essential part 
of what they have to offer their patients.  
Patient Education and Self-Management  
 Encouraging and supporting people with RA to take more con-
trol of their illness by engaging in self-management has increas-
ingly become a focus in many health services. One particular push 
for this approach is the increasing recognition that with an ageing 
population and the consequent increase in the frequency of chronic 
disease, health services will have to change their model for treating 
chronic disease [158]. The primary objectives of patient education 
are to present the rationale for the treatment in an understandable 
way, to elicit active collaboration between patients (and their care-
givers) and the clinician, and to help patients gain confidence in 
their ability to adapt to the consequences of the disease. It is par-
ticularly important to encourage RA patients and spouses to adopt 
the belief that they can learn the skills necessary to cope better with 
the patients' illness-related problems and overcome helplessness. 
Self-management is defined as the extent to which the patient regu-
lates and is responsible for his/her own treatment and care. Self-
management and medical care are more complementary than in-
compatible, and both patients and professionals depend on each 
other to control disease activity and pain and prevent (progression 
of) joint destruction and disability. This dependence includes the 
management of daily activities and medication. 
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 Enabling self-management for people with long-term conditions 
should be part of rheumatology practice. Many rheumatology teams 
provide general education in self-management. However, many 
clinicians are uncertain how to help. 
 The most effective means of providing a self-management pro-
gram is through individual cognitive behavioral therapy, which uses 
a variety of techniques, including cognitive restructuring of dys-
functional beliefs and “worry” thoughts, relaxation training, posi-
tive self-talk, and exposure to anxious situations, thoughts, and 
worries. 
 In cognitive behavioral therapy, the essential self-management 
strategies of problem solving and goal setting improve self-efficacy 
and confidence that one can do something to make a difference. A 
systematic review of general self-management programs in rheu-
matic diseases suggested incorporation of the cognitive behavioral 
therapy and self-efficacy principles [159]. Data suggest that in pa-
tients with RA, cognitive behavioral therapy targeting illness cogni-
tions results in better outcomes [160]. However, any psychological 
intervention should only be provided after a thorough psychiatric 
evaluation. Self-determination theory is popular in the field of self-
management [161]. The basic premise of this theory is that motiva-
tion is determined by 3 basic needs: autonomy, competence, and 
social relatedness. Of these, autonomy takes a central position: if a 
behavior is autonomous, it is voluntary, originating from one’s own 
values, and self- determined. A patient will be more inclined to 
conduct and persist in autonomous behavior than in externally di-
rected behavior. Competence includes the need to feel that one is 
really able to achieve something and is related to the construct of 
self-efficacy. The third basic need, social relatedness, is the extent 
to which one finds support in one’s environment, including one’s 
coach or therapist. High levels of autonomy, competence, and so-
cial relatedness enhance self-management. Motivational interview-
ing is the primary tool for ensuring autonomous motivation [162]. 
Even in the absence of a formal program, research reveals that 
committed health professionals can play an important role in 
enhancing patients’ well-being by promoting self-awareness, 
coping skills to deal with stress, sense of empowerment and 
confidence, and the ability to live with meaning and hope [163].  
Patient Education. Coping Skills 
 To enhance physical and psychological functioning, cognitive- 
behavioral interventions generally try to modify coping strategies 
by addressing dysfunctional thoughts and pain- related behaviors 
with the aim of improving long-term psychological and physical 
outcomes. The purpose of the initial component of training in cop-
ing skills is to help patients and spouses involve actively in the 
process of learning new strategies (eg, relaxation, and pacing of 
activity and daily resting periods) and to replace unhelpful cogni-
tions with helpful ones.  
 This phase enhances self-efficacy, reduces perceptions of help-
lessness, and helps patients to better cope with the disease-related 
problems. Patients and their partners are stimulated to practice and 
integrate these new cognitive and behavioral coping strategies and 
to apply them efficiently at home and at work. In the relapse phase, 
patients are stimulated to continue use of their coping strategies and 
treatment gains. 
 Most well-designed studies on psychosocial interventions in 
RA have highlighted training in relaxation and coping strategies, 
including stress management, avoidance of catastrophizing, and 
positive reinforcement of healthy behavior in order to improve per-
ceptions of control and self-efficacy. These interventions have pro-
duced statistically significant improvements in pain scores, exhibi-
tions of pain behavior, reductions in affected joint counts and im-
provements in patients' scores of helplessness, self-efficacy, disabil-
ity, and distress [151, 152, 164]. Typically, relapses occur when the 
intensity of symptoms begins to increase, since patients’ perception 
of symptom control is diminished, and when patients experience 















Fig. (1). The determinants of “placebo responses”. (Doherty M. and Dieppe P., 2009).  
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Patient Education. Therapeutic Contract: Promoting Adher-
ence 
 The factors most associated with increased adherence to medi-
cation in RA are higher levels of self-efficacy and social support 
[166, 167]. The interested practitioner should promote these factors 
and investigate and correct (where possible) problems with adher-
ence. The cause of such behavior has been addressed by the self-
expectation efficacy theory [168]: adherence is influenced by the 
balance between patients’ beliefs about the need for treatment and 
their concerns about the risks. Communication between physician 
and patient is crucial to adherence. Muller et al. (2012) found that 
patients who were satisfied with their physicians had significantly 
higher levels of adherence than those who were not [48]. Other 
studies have found that improved patient knowledge about the dis-
ease and the medication and a higher frequency of visits to the phy-
sician are correlated with better adherence [169, 170]. In addition, 
more frequent monitoring will increase the chance of early identifi-
cation and control of disease flares, adverse effects, and substantial 
mood changes To promote adherence, practitioners require support 
and training in communicating the benefits and risks of therapies 
and in assessing and incorporating of patients’ beliefs into the con-
sultation process, while policymakers need to reduce barriers to 
access to treatment, such as drug costs where this is relevant [171].  
Working on the Social Environment  
 Invalidation (lack of understanding and discounting by others) 
is a crucial social aspect of disease burden. It includes negative 
social responses (denying, lecturing, and overprotecting), as well as 
a lack of positive social responses (supporting and acknowledging), 
and may represent a significant problem for people with RA [143]. 
Invalidation may actually increase the risk of becoming depressed 
and physically impaired [172], thus highlighting the need to take 
invalidation into account in research and clinical settings [4]. In-
deed, greater satisfaction with emotional support and social com-
panionship are related to reduced distress in patients with RA [173].  
4. CONCLUSION 
 This article reviews the potential psychological determinants, 
mechanisms, and interventions that may be involved in response to 
treatment in RA, including not only disease activity, but also the 
impact of the disease on the patient. The psychological conse-
quences of RA are gaining importance, and PROs are increasingly 
taken into consideration. The psychological burden of RA on 
spouses, relatives, and caregivers is also attracting more attention. 
A true partnership with patients and their caregivers based on edu-
cation, shared decision-making, and self-management is an indis-
pensable tool for ensuring the success of therapy. In parallel, re-
searchers and clinicians now realize that the psychological status of 
patients with RA, especially those with depression, must be taken 
into account in order to achieve the best possible results in a variety 
of relevant outcomes, from immune regulation to pain, disease ac-
tivity, prevention of disability, and quality of life. The biological 
mechanisms underlying these factors, with emphasis on neuroendo-
crine immunology, are becoming increasingly clear, opening novel 
avenues for intervention (Fig. 2).  
 Access to psychological support tailored to the psychological 
needs of the individual patient is warranted for optimal outcome, as 
is conventional treatment. All RA patients should be evaluated for 
depression, and appropriate treatment with antidepressants or psy-
chotherapy should be started when indicated. The potential benefits 
of antidepressive interventions for RA in the absence of depression 
have not been established. Such approaches will facilitate greater 
improvements in the psychological and physical status of people 
with RA, enabling them to live a more fulfilling and possibly also 
longer life.  
5. FUTURE RESEARCH  
 Research is needed to clarify whether inclusion of PROs in 
current disease evaluations can lead to improved relevant outcomes 
for the patient by narrowing the gap between the patient and the 
physician’s perspective. The sensitivity to change of many PROs 
 
Fig. (2). Potential associations between psychological state and response to treatment in RA. In most cases, the root cause remains unclear, although it is most 
probably bidirectional and may change during different phases of the disease course.  
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should be assessed (eg, RAID score). New PROs should be con-
tinuously developed to guarantee that truly relevant domains are 
covered in a cross-culturally valid way. Instruments such as the 
Personal Life Impact Measurement Scales seem especially promis-
ing [174, 175]. Studies addressing the influence of psychological 
variables on response to medication in randomized controlled trials 
are urgently needed, as are new efforts and training to foster our 
understanding of coping strategies, by focusing on longitudinal and 
within- person research designs (eg, daily diary studies). Outcome 
criteria should be related to the autonomous needs and goals of each 
patient, namely, preserving autonomy, social relationships, and 
valued activities. 
 Available evidence indicates the need for a trial on the potential 
role of antidepressant medication in patients with RA. The indica-
tion is obvious in the presence of comorbid depression, as this di-
rectly impacts the patient’s quality of life. However, the immuno-
modulatory effects of antidepressants and the presence of biological 
pathways that are common to depression and RA support the hy-
pothesis that antidepressants may have positive effects on RA, even 
in the absence of depression. Basic and clinical research designed to 
understand the biological pathways involved in interactions be-
tween disease process and psychosocial domains will play a key 
role in opening new avenues of intervention. 
CONFLICT OF INTEREST 
 The authors confirm that this article content has no conflict of 
interest. 
ACKNOWLEDGEMENTS 
 Declared none. 
ABBREVIATIONS  
ACR = American College of Rheumatology 
CRH = Corticotrophin-releasing hormone 
CRP = C-reactive protein  
DAS28 = Disease activity score including the assessment of 
28 joints  
ESR = Erythrocyte sedimentation rate 
HPA = Hypothalamic-pituitary-adrenal 
HAQ = Health assessment questionnaire  
IL = Interleukin  
MTX = Methotrexate 
PLIMS = Personal Life Impact Measurement Scales  
PROs = Patient-reported outcomes  
RA = Rheumatoid arthritis  
RAID = Rheumatoid Arthritis Impact of Disease 
SSRI = Selective serotonin reuptake inhibitor  
TNF = Tumor necrosis factor 
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